Rituximab Immunotherapy for Autoimmune Premature Ovarian Insufficiency: What the Karolinska Pilot Study Found

A single infusion of rituximab, an approved B-cell-depleting antibody, enabled ovarian follicle retrieval in half of treated women and led to healthy births in three out of ten women with autoimmune premature ovarian insufficiency (POI), according to a proof-of-concept pilot study from Karolinska Institutet published in NEJM Evidence on June 23, 2025. The findings mark the first controlled evidence that immunomodulatory therapy can temporarily restore fertility in some women with this condition — but the investigators emphasize that the results are preliminary and require confirmation through a larger, rigorous trial now underway .

What the study found: follicles and live births

Among the ten women with autoimmune POI who completed the study:

• 5 of 10 women (50%) developed retrievable follicles after rituximab treatment. None of the women had retrievable follicles before treatment .
• 3 of 10 women (30%) subsequently gave birth to healthy babies .

The study included 12 women aged 18–35, but two withdrew before treatment began .

How rituximab works in autoimmune POI

Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen expressed on B lymphocytes. By binding to CD20, it induces temporary B-cell depletion, which suppresses the autoimmune attack against ovarian tissue. This allows residual ovarian follicles — which remain intact in some women with autoimmune POI — to become responsive again to gonadotropin stimulation, enabling egg maturation and retrieval .

Autoimmune POI accounts for about 4.5% of all POI cases, as judged by the presence of steroidogenic autoantibodies against 21-hydroxylase and side-chain cleavage enzyme . In these patients, the immune system mistakenly attacks the ovarian follicles, leading to early menopause and infertility. The rationale for using rituximab is that temporarily removing B cells could halt this attack long enough for hormone stimulation to work.

Key limitations: a proof-of-concept study

The study was explicitly described as a proof-of-concept design without a control group . Other important limitations include:

• Small sample size (n=10). The lack of statistical power means no definitive conclusions about efficacy can be drawn from this pilot alone .
• No randomization or blinding. The open-label design introduces potential bias .
• No placebo comparison. Without a placebo group, it is impossible to rule out the possibility that some women would have improved spontaneously or due to other factors.

As a result, the researchers caution that these findings are not yet sufficient to support clinical recommendations. The study should be interpreted as a signal — not proof — that rituximab may benefit a subset of women with autoimmune POI.

Follow-up: Phase 3 randomized trial now recruiting

A larger, more rigorous trial is already underway to confirm these findings. The study — titled "Immunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian Insufficiency" (ClinicalTrials.gov identifier NCT07509840) — is a randomized, double-blind, placebo-controlled phase 3 trial .

Key details of the ongoing phase 3 trial:

Detail	Information
Phase	Phase 3
Design	Double-blind, placebo-controlled, randomized
Target enrollment	40 participants
Primary endpoint	Egg retrieval in response to controlled ovarian hyperstimulation
Start date	February 12, 2026
Sites	Multiple sites in one country

The phase 3 trial aims to validate the pilot results in a larger, rigorously controlled setting before any clinical recommendation can be made . Another related study (NCT05586737) is also investigating the effects of rituximab on ovarian function in women with autoimmune POI .

Clinical context: where rituximab fits for POI

No therapy for infertility due to autoimmune POI has yet been proven effective by a prospective, randomized, placebo-controlled study . Previous attempts using corticosteroids and other immunosuppressants have shown mixed results and potential for serious complications, leading experts to call for restricting such therapies to controlled trials .

The Karolinska pilot study represents a significant step forward because it is the first to show successful outcomes using targeted B-cell depletion in this population. However, the need for a placebo-controlled trial remains urgent .

For now, women with autoimmune POI seeking fertility treatment should discuss their options — including standard hormone replacement, ovarian stimulation protocols, and potential participation in clinical trials — with a reproductive endocrinologist. Rituximab therapy for POI is not yet recommended outside of research settings.

The takeaway

The Karolinska Institutet pilot study provides the first evidence that rituximab-based immunotherapy can restore fertility in some women with autoimmune POI. Half of the treated women developed retrievable follicles, and three gave birth to healthy babies. But because the study was small and lacked a control group, these results are best viewed as a promising signal — one that will be tested rigorously in the phase 3 trial now recruiting.